| Literature DB >> 26273018 |
Liangyu Ge1,2, Siyu Liu1,2, Long Xie1,2, Lei Sang3, Changyan Ma4, Hongwei Li1,5.
Abstract
Differentially expressed genes are thought to regulate the development and progression of oral squamous cell carcinomas (OSCC). The purpose of this study was to screen differentially expressed mRNAs in OSCC and matched paraneoplastic normal tissues, and to explore the intrinsic mechanism of OSCC development and progression. We obtained the differentially expressed mRNA expression profiles in 10 pairs of fresh-frozen OSCC tissue specimens and matched paraneoplastic normal tissue specimens by high-throughput RNA sequencing. By using Gene Ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, the functional significance of the differentially expressed genes were analyzed. We identified 1,120 significantly up-regulated mRNAs and 178 significantly down-regulated mRNAs in OSCC, compared to normal tissue. The differentially expressed mRNAs were involved in 20 biological processes and 68 signal pathways. Compared to adjacent normal tissue, the expression of MAGEA11 was up-regulated; TCHH was down-regulated. These findings were verified by real-time PCR. These differentially expressed mRNAs may function as oncogenes or tumor suppressors in the development and progression of OSCC. This study provides novel insights into OSCC. However, further work is needed to determine if these differentially expressed mRNAs have potential roles as diagnostic biomarkers and candidate therapeutic targets for OSCC.Entities:
Keywords: Gene Ontology; KEGG pathway; high-throughput RNA sequencing; mRNA; oral squamous cell carcinoma
Year: 2015 PMID: 26273018 PMCID: PMC4585435 DOI: 10.7555/JBR.29.20140088
Source DB: PubMed Journal: J Biomed Res ISSN: 1674-8301
Clinicopathologic data of 10 patients included in the study
| Variables | |
|---|---|
| Male sex, | 6(60) |
| Age, years, | |
| ≤ 50 | 2(20) |
| 51–60 | 3(30) |
| 61–70 | 3(30) |
| ≥ 71 | 2(20) |
| Location, | |
| Bucca mucosa | 4(40) |
| Tongue | 4(40) |
| Gingiva | 2(20) |
| Grade | |
| I | 3(30) |
| II | 6(60) |
| III | 1(10) |
| TNM staging, | |
| T1 | 7(70) |
| T2 | 3(30) |
| N = 0 | 4(40) |
| N>0 | 6(6) |
| Mean size(SD), cm3 | 2.75(1.54) |
The 10 most up-regulated and down-regulated mRNAs in OSCC
| Up-regulated in OSCC | Down-regulated in OSCC | ||||
|---|---|---|---|---|---|
| mRNA | log2Ratio | mRNA | log2Ratio | ||
| MAGEA11 | 2.96E-13 | 10.25267 | TCHH | 4.41E-18 | −10.7599 |
| PHACTR3 | 9.44E-11 | 9.930737 | SYTL4 | 1.57E-08 | −9.60733 |
| COL10A1 | 3.99E-10 | 9.837628 | EPHX3 | 2.26E-07 | −9.37721 |
| PPAPDC1A | 1.68E-09 | 9.738092 | KRT33B | 1.23E-05 | −8.93958 |
| EMR1 | 3.46E-09 | 9.686501 | CTTNBP2 | 2.40E-05 | −8.85175 |
| FAM132A | 3.46E-09 | 9.686501 | ESYT3 | 4.67E-05 | −8.75822 |
| CHRNA1 | 3.46E-09 | 9.686501 | NCRNA00162 | 4.67E-05 | −8.75822 |
| LRRC17 | 7.12E-09 | 9.631177 | SYTL5 | 4.67E-05 | −8.75822 |
| ODZ3 | 6.18E-08 | 9.455327 | CACNB4 | 4.67E-05 | −8.75822 |
| BAALC | 2.61E-07 | 9.324181 | CRTAC1 | 9.10E-05 | −8.66178 |
Cellular distribution of the DEGs
| Cluster frequency | |||
|---|---|---|---|
| Gene Ontology term | Count | % | Corrected |
| Extracellular region part | 154 | 13.6 | 2.54E-15 |
| Extracellular region | 156 | 13.8 | 2.69E-15 |
| Extracellular matrix | 65 | 5.7 | 2.63E-12 |
| Extracellular matrix part | 20 | 1.8 | 1.00E-08 |
| Proteinaceous extracellular matrix | 27 | 2.4 | 7.57E-06 |
| Collagen | 10 | 0.9 | 1.64E-05 |
| Cytoplasm | 362 | 32.0 | 3.50E-05 |
| Cytoplasmic part | 360 | 31.8 | 4.52E-05 |
| Endoplasmic reticulum part | 34 | 3.0 | 0.00929 |
| Macromolecular complex | 252 | 22.2 | 0.01500 |
| Fibrillar collagen | 4 | 0.4 | 0.02594 |
DEGs: differentially expressed genes
Molecular function of the DEGs
| Cluster frequency | |||
|---|---|---|---|
| Gene Ontology term | Count | % | Corrected |
| Endopeptidase activity | 60 | 5.7% | 9.09E-07 |
| Growth factor binding | 22 | 2.1 | 4.19E-05 |
| Peptidase activity | 70 | 6.7 | 0.00090 |
| Protein binding | 354 | 33.8 | 0.00130 |
| Peptidase activity, acting on L-amino acid peptides | 69 | 6.6 | 0.00131 |
| Oxidoreductase activity | 69 | 6.6 | 0.02030 |
| Cytokine activity | 12 | 1.1 | 0.04538 |
Fig. 1Expression of MAGEA11 (A) and TCHH (B) in OSCC tissues.
A: MRNA transcript levels MAGEA11 and B: TCHH in oral squamous cell carcinoma (OSCC) tissues n = 15, *P < 0.05 vs. normal controls.
Biological process associated with DEGs
| Cluster frequency | |||
|---|---|---|---|
| Gene Ontology term | Count | % | Corrected |
| Extracellular structure organization | 32 | 3.0 | 3.62E-05 |
| Immune system process | 119 | 11.3 | 0.00012 |
| Response to wounding | 42 | 4.0 | 0.00036 |
| Regulation of multicellular organismal development | 60 | 5.7 | 0.00240 |
| Cell motility | 72 | 6.8 | 0.00266 |
| Localization of cell | 72 | 6.8 | 0.00266 |
| Cellular component movement | 72 | 6.8 | 0.00343 |
| Collagen metabolic process | 10 | 0.9 | 0.00379 |
| Locomotion | 82 | 7.8 | 0.00629 |
| Multicellular organismal macromolecule metabolic process | 11 | 1.0 | 0.00768 |
| Extracellular matrix organization | 14 | 1.3 | 0.00979 |
| Anatomical structure development | 271 | 25.6 | 0.01196 |
| Regulation of developmental process | 85 | 8.0 | 0.01237 |
| Cell migration | 59 | 5.6 | 0.01513 |
| Multicellular organismal metabolic process | 11 | 1.0 | 0.01541 |
| Response to organic substance | 108 | 10.2 | 0.01566 |
| Tissue development | 91 | 8.6 | 0.02052 |
| Developmental process | 316 | 29.9 | 0.03336 |
| Response to stimulus | 298 | 28.2 | 0.03626 |
| Signal transmission via phosphorylation event | 68 | 6.4 | 0.03752 |
The DEGs with pathway annotation
| DEGs with pathway annotation | |||
|---|---|---|---|
| Pathway | Count | % | |
| ECM-receptor interaction | 37 | 3.53 | 6.620198E-05 |
| Rheumatoid arthritis | 22 | 2.1 | 1.021563E-04 |
| Focal adhesion | 58 | 5.53 | 1.021563E-04 |
| Antigen processing and presentation | 23 | 2.19 | 2.146282E-04 |
| Type I diabetes mellitus | 14 | 1.33 | 1.137989E-03 |
| Graft-versus-host disease | 14 | 1.33 | 5.377383E-03 |
| Lysosome | 26 | 2.48 | 7.047030E-03 |
| Amoebiasis | 30 | 2.86 | 8.074916E-03 |
| Allograft rejection | 11 | 1.05 | 1.000477E-02 |
| Pathways in cancer | 56 | 5.34 | 1.178707E-02 |